Aurobindo Pharma Limited
AUROPHARMA · Pharma · NSE
₹1,473
Current Market Price
Fair Value (DCF)
₹1,546
Discount to FV
+5.0%
Updated just now
YieldIQ Score
59/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
54%
ROE
9.2%
Debt/Equity
0.21
WACC
10.5%
Market Cap
₹84,742 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.8%
Return on capital employed
EV / EBITDA
10.4×
Enterprise multiple
Debt / EBITDA
1.1×
Leverage vs earnings
Interest Coverage
14.3×
EBIT covers interest
Current Ratio
1.81×
Short-term liquidity
Asset Turnover
0.58×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.7%
3-year revenue growth
Revenue CAGR (5Y)
16.1%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,472.8
Bear case
Margin of Safety -128.8%
Implied upside -56.3%
Base case
Margin of Safety +4.5%
Implied upside +4.7%
Bull case
Margin of Safety +22.8%
Implied upside +29.6%
Ratio Trends
AUROPHARMA · last 8 annual periods
ROE
9.2%
ROCE
15.8%
Operating Margin
—
Debt / Equity
0.21×
PE
21.4×
EV / EBITDA
10.4×
Historical Financials
AUROPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹23.4K Cr | ₹24.6K Cr | ₹28.7K Cr | ₹31.4K Cr | ₹33.4K Cr | +9.3% |
| EBITDA | ₹4536 Cr | ₹3986 Cr | ₹6140 Cr | ₹7173 Cr | ₹7274 Cr | +12.5% |
| EBIT | ₹3453 Cr | ₹2765 Cr | ₹4687 Cr | — | — | +7.9% |
| PAT | ₹2648 Cr | ₹1928 Cr | ₹3173 Cr | ₹3486 Cr | ₹3505 Cr | +7.3% |
| EPS (diluted) | ₹45.19 | ₹32.90 | ₹54.16 | — | — | +4.6% |
| CFO | ₹5016 Cr | ₹2387 Cr | ₹2435 Cr | ₹3925 Cr | ₹5526 Cr | +2.4% |
| CapEx | ₹-2705 Cr | ₹-2720 Cr | ₹-3562 Cr | ₹-2520 Cr | ₹-3105 Cr | — |
| FCF | ₹2312 Cr | ₹-334 Cr | ₹-1127 Cr | ₹1405 Cr | ₹2422 Cr | +1.2% |
| Total Assets | ₹33.9K Cr | ₹39.9K Cr | ₹45.1K Cr | ₹49.8K Cr | ₹58.5K Cr | +14.6% |
| Total Debt | ₹3279 Cr | ₹5286 Cr | ₹6648 Cr | ₹8263 Cr | ₹8073 Cr | +25.3% |
| Shareholders' Equity | ₹24.6K Cr | ₹26.8K Cr | ₹29.8K Cr | ₹32.7K Cr | ₹37.9K Cr | +11.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AUROPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 LAURUSLABS LAURUSLABS | — | — | Pending | 8.0% | — |
 MANKIND MANKIND | — | — | Pending | 11.7% | — |
 LUPIN Lupin Limited | +16.7%+20.1% upside | 52 | Near Fair Value | 23.8% | 19.8× |
 BIOCON BIOCON | — | — | Pending | 1.1% | 151.6× |
 DRREDDY Dr. Reddy's Laboratories Limited | +10.8%+12.1% upside | 55 | Near Fair Value | 11.4% | 24.4× |
Click a ticker to view its fair-value analysis.
Dividend History
20 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹20.50/sh
Last payout
2025-08-08
₹4.00
Peak payout
₹4.50
Trailing yield
0.27%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Aurobindo Pharma Limited (AUROPHARMA.NS) trades at 1472.80 vs a model fair value of 1546.00, a gap of 5.0%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AUROPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AUROPHARMA →
Compare
Head-to-head with peers
Compare AUROPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AUROPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.